Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mikkel Algire

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Nature Biotechnology|December 9, 2010
Megabases for kilodollarsMikkel Algire, Radha Krishnakumar, Chuck Merryman
ACS Medicinal Chemistry Letters|June 24, 2015
Discovery of A-893, A New Cell-Active Benzoxazinone Inhibitor of Lysine Methyltransferase SMYD2Ramzi F Sweis, Zhi Wang, Mikkel Algire, et al.
ACS Medicinal Chemistry Letters|May 31, 2021
Discovery of a Potent and Selective Covalent p300/CBP InhibitorAnthony Mastracchio, Chunqiu Lai, Enrico Digiammarino, et al.
Bioorganic & Medicinal Chemistry Letters|February 25, 2021
Discovery of spirohydantoins as selective, orally bioavailable inhibitors of p300/CBP histone acetyltransferasesZhiqin Ji, Richard F Clark, Vikram Bhat, et al.
Journal of Medicinal Chemistry|March 6, 2023
Discovery of a Potent Chloroacetamide GPX4 Inhibitor with Bioavailability to Enable Target Engagement in Mice, a Potential Tool Compound for Inducing Ferroptosis <i>In Vivo</i>John T Randolph, Matthew J O'Connor, Fei Han, et al.
Nature|September 28, 2017
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumoursLoren M Lasko, Clarissa G Jakob, Rohinton P Edalji, et al.
Nature|May 18, 2018
Author Correction: Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumoursLoren M Lasko, Clarissa G Jakob, Rohinton P Edalji, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Nature Biotechnology|December 9, 2010
Megabases for kilodollarsMikkel Algire, Radha Krishnakumar, Chuck Merryman
ACS Medicinal Chemistry Letters|June 24, 2015
Discovery of A-893, A New Cell-Active Benzoxazinone Inhibitor of Lysine Methyltransferase SMYD2Ramzi F Sweis, Zhi Wang, Mikkel Algire, et al.
ACS Medicinal Chemistry Letters|May 31, 2021
Discovery of a Potent and Selective Covalent p300/CBP InhibitorAnthony Mastracchio, Chunqiu Lai, Enrico Digiammarino, et al.
Bioorganic & Medicinal Chemistry Letters|February 25, 2021
Discovery of spirohydantoins as selective, orally bioavailable inhibitors of p300/CBP histone acetyltransferasesZhiqin Ji, Richard F Clark, Vikram Bhat, et al.
Journal of Medicinal Chemistry|March 6, 2023
Discovery of a Potent Chloroacetamide GPX4 Inhibitor with Bioavailability to Enable Target Engagement in Mice, a Potential Tool Compound for Inducing Ferroptosis <i>In Vivo</i>John T Randolph, Matthew J O'Connor, Fei Han, et al.
Nature|September 28, 2017
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumoursLoren M Lasko, Clarissa G Jakob, Rohinton P Edalji, et al.
Nature|May 18, 2018
Author Correction: Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumoursLoren M Lasko, Clarissa G Jakob, Rohinton P Edalji, et al.
Pageof 1